Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This Phase 2a clinical study is designed to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine administered IM, confirm the dose level and regimen, and expand immunogenicity and safety data to adults through age 65.
Epistemonikos ID: c8652da87c1967cd70f9a53cd98d7d37244774a5
First added on: May 06, 2024